TABLE 1.
Relative hepatic mRNA levels
| Chow |
HFD |
|||
|---|---|---|---|---|
| Con. ASO | CGI ASO | Con. ASO | CGI ASO | |
| Lipogenesis | ||||
| SREBP-1c | 1 | 0.69 | 1.18 | 0.53 |
| FAS | 1 | 0.63 | 2.71 | 0.66 |
| ACC1 | 1 | 0.67 | 1.71 | 0.62 |
| SCD-1 | 1 | 0.42 | 3.07 | 0.65 |
| ME | 1 | 0.31 | 2.03 | 0.26 |
| GPAT | 1 | 0.42 | 1.91 | 0.8 |
| DGAT2 | 1 | 0.55 | 1.19 | 0.46 |
| Fatty acid transport and oxidation | ||||
| FATP-1 | 1 | 0.54 | 0.9 | 0.5 |
| PPAR-α | 1 | 0.8 | 1.37 | 0.61 |
| PGC-1α | 1 | 2.06 | 1.59 | 1.14 |
| CPT-1α | 1 | 1.04 | 1.15 | 0.65 |
| ACO | 1 | 0.58 | 1.25 | 0.53 |
| LCAD | 1 | 0.85 | 1.4 | 0.73 |
| HMGCS2 | 1 | 0.55 | 1.26 | 0.48 |
| FGF21 | 1 | 0.68 | 0.14 | 0.96 |
| PPAR-γ and its targets | ||||
| PPAR-γ | 1 | 0.82 | 1.07 | 1.17 |
| aP2 | 1 | 1.99 | 1.09 | 2.45 |
| CD36 | 1 | 1.88 | 1.64 | 2.51 |
| Glucose metabolism and insulin signaling | ||||
| GK | 1 | 0.97 | 1.85 | 0.91 |
| PEPCK | 1 | 0.9 | 1.06 | 0.47 |
| G6P | 1 | 0.61 | 1.39 | 0.25 |
| GLUT2 | 1 | 0.65 | 1.23 | 0.58 |
| ChREBP | 1 | 0.61 | 0.88 | 0.4 |
| FOXO1 | 1 | 0.54 | 1.11 | 0.74 |
| IRS2 | 1 | 0.64 | 0.48 | 0.53 |
| Cholesterol synthesis | ||||
| SREBP-2 | 1 | 0.74 | 0.85 | 0.36 |
| HMGCS | 1 | 0.55 | 0.79 | 0.22 |
| HMGCR | 1 | 1.21 | 1.24 | 0.9 |
| Triglyceride hydrolysis | ||||
| CGI-58 | 1 | 0.01 | 1.16 | 0.02 |
| ATGL | 1 | 1.59 | 0.9 | 0.71 |
Liver tissues were collected from male C57BL/6 mice treated with control (Con.) ASO or CGI-58β ASO (CGI ASO) for 8 weeks and the total RNA was extracted from individual liver samples. An equal amount of total RNA from each sample in each group (n = 5) was pooled and subjected to qPCR as described in Materials and Methods. LCAD, long-chain acyl-CoA dehydrogenase; ME, malic enzyme.